These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 26531233)

  • 1. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
    Zuo Y; Shi Y; Li X; Teng Y; Pan Z
    Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
    Li X; Zuo Y; Tang G; Wang Y; Zhou Y; Wang X; Guo T; Xia M; Ding N; Pan Z
    J Med Chem; 2014 Jun; 57(12):5112-28. PubMed ID: 24915291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors.
    Zou Y; Xiao J; Tu Z; Zhang Y; Yao K; Luo M; Ding K; Zhang Y; Lai Y
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3052-3059. PubMed ID: 27210433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
    Huang Z; Zhang Q; Yan L; Zhong G; Zhang L; Tan X; Wang Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1954-7. PubMed ID: 26976214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Zheng N; Pan J; Hao Q; Li Y; Zhou W
    Bioorg Med Chem; 2018 May; 26(8):2165-2172. PubMed ID: 29567295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
    Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
    Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
    Zhao D; Huang S; Qu M; Wang C; Liu Z; Li Z; Peng J; Liu K; Li Y; Ma X; Shu X
    Eur J Med Chem; 2017 Jan; 126():444-455. PubMed ID: 27912175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.
    Turetsky A; Kim E; Kohler RH; Miller MA; Weissleder R
    Sci Rep; 2014 Apr; 4():4782. PubMed ID: 24759210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
    Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
    Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
    Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
    Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
    Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
    Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
    Bavi R; Kumar R; Choi L; Woo Lee K
    PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
    Liu H; Qu M; Xu L; Han X; Wang C; Shu X; Yao J; Liu K; Peng J; Li Y; Ma X
    Eur J Med Chem; 2017 Jul; 135():60-69. PubMed ID: 28432946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
    Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
    Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Bruton's Tyrosine Kinase Inhibitors for Rheumatoid Arthritis.
    Lv J; Wu J; He F; Qu Y; Zhang Q; Yu C
    Curr Med Chem; 2018; 25(42):5847-5859. PubMed ID: 29546831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.
    Lin L; Czerwinski R; Kelleher K; Siegel MM; Wu P; Kriz R; Aulabaugh A; Stahl M
    Biochemistry; 2009 Mar; 48(9):2021-32. PubMed ID: 19206206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.